Sun Pharmaceutical Industries Ltd Gains 0.22%: Mixed Technical Signals and Market Activity Shape the Week
2026-11-21 14:04:55Key Events This Week 16 Nov: Stock opens at Rs.1,866.95, declines 0.74% 18 Nov: Death Cross forms, signalling potential bearish trend 19 Nov: Sharp open interest surge amid bullish momentum 19 Nov: Mojo Grade downgraded to Sell 20 Nov: Technical momentum shifts amid mixed indicator signals Week OpenRs.1,880.90 <div class="stat...
Read More
Sun Pharmaceutical Industries Ltd Technical Momentum Shifts Amid Mixed Indicator Signals
2026-11-20 08:03:42Sun Pharmaceutical Industries Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Despite a recent upgrade in its technical outlook, the stock’s overall Mojo Grade has been downgraded from Hold to Sell, reflecting a complex interplay of bullish and bearish signals across multiple timeframes and indicators.
Read More
Sun Pharmaceutical Industries Sees Sharp Open Interest Surge Amid Bullish Momentum
2026-11-19 15:00:59Sun Pharmaceutical Industries Ltd has witnessed a notable surge in open interest in its derivatives segment, signalling increased market participation and potential directional bets. The stock’s recent outperformance relative to its sector and sustained gains over the past three sessions have coincided with this spike, prompting a closer examination of volume patterns, market positioning, and implications for investors.
Read More
Sun Pharmaceutical Industries Downgraded to Sell Amid Technical and Financial Concerns
2026-11-19 08:35:54Sun Pharmaceutical Industries Ltd has seen its investment rating downgraded from Hold to Sell, driven primarily by a deterioration in technical indicators, flat financial performance, and valuation concerns. Despite its status as a large-cap leader in the Pharmaceuticals & Biotechnology sector, recent quarterly results and promoter stake reductions have raised caution among analysts, prompting a reassessment of the stock’s outlook.
Read More
Sun Pharmaceutical Industries Ltd Faces Mildly Bearish Technical Shift Amid Mixed Momentum Signals
2026-11-19 08:04:42Sun Pharmaceutical Industries Ltd has experienced a subtle but notable shift in its technical momentum, moving from a mildly bullish stance to a mildly bearish outlook. Despite a modest day change of 0.12%, the stock’s technical indicators reveal a complex interplay of signals that investors should carefully analyse amid evolving market conditions.
Read More
Sun Pharmaceutical Industries Ltd Forms Death Cross Signalling Potential Bearish Trend
2026-11-18 18:00:54Sun Pharmaceutical Industries Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average, signalling a potential shift towards a bearish trend and long-term weakness in the stock’s price momentum.
Read MoreP/E at 36.45 vs Industry's 39.31: What the Data Shows for Sun Pharmaceutical Industries Ltd
2026-11-18 09:20:53Valuation Picture: A Slight Discount in a High-P/E Industry Sun Pharmaceutical Industries Ltd trades at a P/E of 36.45, which is approximately 7.3% below the Pharmaceuticals & Biotechnology sector average of 39.31. This discount suggests that the market is pricing in either a more conservative growth outlook or risk factors relative to peers. Given the sector's elevated valuation levels, this positioning could reflect a cautious stance despite the company's large-cap status and established market presence. The P/E differential invites the question previously ra...
Read MoreP/E at 36.39 vs Industry's 39.33: What the Data Shows for Sun Pharmaceutical Industries Ltd
2026-11-17 09:21:39Valuation Picture: A Slight Discount in a High-P/E Sector Sun Pharmaceutical Industries Ltd trades at a P/E of 36.39, which is approximately 7.5% below the Pharmaceuticals & Biotechnology sector average of 39.33. This valuation discount suggests the market is pricing in either a more cautious outlook on the company's near-term earnings growth or a premium being assigned elsewhere within the sector. The sector itself is characterised by elevated valuations, reflecting strong growth expectations and innovation-driven prospects. The stock’s relative valuation position raises the question <a href="https://www.marketsmojo.com/stocks-analysis/sun-pharma.ind...
Read MoreP/E at 36.78 vs Industry's 39.79: What the Data Shows for Sun Pharmaceutical Industries Ltd
2026-11-13 09:21:02Valuation Picture: Slight Discount Amid Sector Premiums The current P/E of Sun Pharmaceutical Industries Ltd stands at 36.78, which is approximately 7.6% below the sector average of 39.79. This valuation gap suggests that the stock is trading at a modest discount relative to its pharmaceutical peers. Given the sector's elevated valuations, this discount could reflect investor caution or a recalibration of growth expectations. The P/E differential is notable because it contrasts with the stock's large-cap status and its historical premium pricing. Sun Pharmaceut...
Read MoreAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
05-Nov-2026 | Source : BSEIntimation of Schedule of Analyst/Institutional Investor Meeting
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
04-Nov-2026 | Source : BSEQ2FY27 Earnings Call Transcript
Clarification Sought From Sun Pharmaceutical Industries Ltd
02-Nov-2026 | Source : BSEThe Exchange has sought clarification from Sun Pharmaceutical Industries Ltd on November 2 2026 with reference to news appeared in https://www.thehindu.com/ dated October 30 2026 quoting "India orders Sun Pharma to halt eye-care drug production at plant after quality lapses" .
The reply is awaited.
Corporate Actions
No Upcoming Board Meetings
Sun Pharmaceutical Industries Ltd has declared 500% dividend, ex-date: 07 Jul 26
Sun Pharmaceutical Industries Ltd has announced 1:5 stock split, ex-date: 25 Nov 10
Sun Pharmaceutical Industries Ltd has announced 1:1 bonus issue, ex-date: 29 Jul 13
No Rights history available